Shop GLP-1 Research Peptides

Semaglutide is a single-pathway GLP-1 receptor agonist. Tirzepatide is a dual agonist that also activates the GIP receptor. Retatrutide goes a step further as a triple agonist, adding glucagon receptor activity on top of GIP and GLP-1. Each additional pathway changes the metabolic research profile, which is why they're studied separately rather than treated as versions of the same compound.

Cagrilintide is an amylin-analog peptide, not a GLP-1 agonist — it works through a different receptor system entirely, which is why it's frequently studied alongside GLP-1 compounds rather than instead of them. Combination research protocols pairing it with Semaglutide or Retatrutide are one of the more active areas of current literature.

Unreconstituted, keep them refrigerated (2–8°C) or frozen for longer-term storage, protected from light. After reconstitution with bacteriostatic water, standard protocol is refrigeration and use within roughly 3–4 weeks — check the specific stability data for the compound you're working with, since it varies slightly by peptide.

It means exactly what it says: these compounds are sold for laboratory and research purposes, not for human or animal consumption, and they haven't been evaluated by any regulatory body as a drug or treatment. That's the standard basis on which research peptides are sold industry-wide, and it's the framework all of our compounds are supplied under.

Different research protocols call for different concentrations, and offering a range (rather than a single strength) means researchers aren't diluting or combining vials to hit the concentration their protocol requires. It's a convenience and precision issue, not an indication of different formulations.